litlas
ログインアカウント作成

Moshe Talpaz

1983–2025 年に発表

254
論文数
60,540
被引用数
124
h 指数
249
i10 指数

被引用数

Moshe Talpaz の年別被引用数1979 年: 被引用 5 件1984 年: 被引用 3 件1985 年: 被引用 7 件1986 年: 被引用 23 件1987 年: 被引用 32 件1988 年: 被引用 33 件1989 年: 被引用 36 件1990 年: 被引用 53 件1991 年: 被引用 78 件1992 年: 被引用 58 件1993 年: 被引用 87 件1994 年: 被引用 89 件1995 年: 被引用 83 件1996 年: 被引用 102 件1997 年: 被引用 81 件1998 年: 被引用 96 件1999 年: 被引用 153 件2000 年: 被引用 170 件2001 年: 被引用 244 件2002 年: 被引用 621 件2003 年: 被引用 771 件2004 年: 被引用 549 件2005 年: 被引用 450 件2006 年: 被引用 553 件2007 年: 被引用 593 件2008 年: 被引用 470 件2009 年: 被引用 483 件2010 年: 被引用 342 件2011 年: 被引用 351 件2012 年: 被引用 346 件2013 年: 被引用 389 件2014 年: 被引用 373 件2015 年: 被引用 433 件2016 年: 被引用 404 件2017 年: 被引用 341 件2018 年: 被引用 321 件2019 年: 被引用 1,115 件2020 年: 被引用 1,371 件2021 年: 被引用 1,203 件2022 年: 被引用 969 件2023 年: 被引用 669 件2024 年: 被引用 1,136 件2025 年: 被引用 444 件2026 年: 被引用 8 件1980〜1983 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 5,531 件、この内訳の 33.3%イギリス: 引用元論文 1,110 件、この内訳の 6.7%中国: 引用元論文 1,094 件、この内訳の 6.6%ドイツ: 引用元論文 1,061 件、この内訳の 6.4%イタリア: 引用元論文 1,036 件、この内訳の 6.2%フランス: 引用元論文 760 件、この内訳の 4.6%カナダ: 引用元論文 523 件、この内訳の 3.2%オーストラリア: 引用元論文 460 件、この内訳の 2.8%スイス: 引用元論文 425 件、この内訳の 2.6%スペイン: 引用元論文 415 件、この内訳の 2.5%日本: 引用元論文 411 件、この内訳の 2.5%オランダ: 引用元論文 389 件、この内訳の 2.3%
0%33.3%その他 20.3%

機関

分野

  • Medicine66%
  • Biochemistry, Genetics and Molecular Biology26.7%
  • Immunology and Microbiology3.3%
  • Computer Science0.9%
  • Neuroscience0.6%
  • Chemistry0.5%
  • その他2%

トピック

  • Chronic Myeloid Leukemia Treatments9%
  • Chronic Lymphocytic Leukemia Research5.1%
  • Eosinophilic Disorders and Syndromes4.2%
  • Acute Myeloid Leukemia Research4%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment3.4%
  • Cancer Genomics and Diagnostics2.7%
  • その他71.6%

共著者

全論文

検索で開く
  1. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    著者: Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson‐Viitanen, Iphigenia L. Koumenis, William Sun, Victor Sandor, Hagop M. Kantarjian - New England Journal of Medicine 2012 被引用: 2,050

  2. Integrative clinical genomics of metastatic cancer

    著者: Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro, Pankaj Vats, Erin Cobain, Jessica Everett, Xuhong Cao, Erica Rabban, Chandan Kumar-Sinha, Victoria Raymond, Scott Schuetze, Ajjai Alva, Javed Siddiqui, Rashmi Chugh, Francis Worden, Mark M. Zalupski, Jeffrey W. Innis, Rajen J. Mody, Scott A. Tomlins, David Lucas, Laurence H. Baker, Nithya Ramnath, Ann F. Schott, Daniel F. Hayes, Joseph Vijai, Kenneth Offit, Elena M. Stoffel, J. Scott Roberts, David C. Smith, Lakshmi P. Kunju, Moshe Talpaz, Marcin Cieslik, Arul M. Chinnaiyan - Nature, Nat. 2017 被引用: 938

  3. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

    著者: Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes, Hironobu Minami, Delphine Réa, Daniel J. DeAngelo, Massimo Breccia, Yeow-Tee Goh, Moshe Talpaz, Andreas Hochhaus, Philipp le Coutre, Oliver G. Ottmann, Michael C. Heinrich, Juan Luis Steegmann, Michael W. Deininger, Jeroen J. W. M. Janssen, François-Xavier Mahon, Yosuke Minami, David T Yeung, David M. Ross, Martin S. Tallman, Jae H. Park, Brian Druker, David Hynds, Yuyan Duan, Christophe Meille, Florence Hourcade‐Potelleret, K. Gary J. Vanasse, Fabian Lang, Dong‐Wook Kim - New England Journal of Medicine 2019 被引用: 467

  4. Activating ESR1 mutations in hormone-resistant metastatic breast cancer

    著者: Dan R. Robinson, Yi-Mi Wu, Pankaj Vats, Fengyun Su, Robert J. Lonigro, Xuhong Cao, Shanker Kalyana‐Sundaram, Rui Wang, Ning Yu, Lynda Hodges, Amy Gursky, Javed Siddiqui, Scott A. Tomlins, Sameek Roychowdhury, Kenneth J. Pienta, Scott Y. H. Kim, Jens Rueter, James M. Rae, Catherine Van Poznak, Daniel F. Hayes, Rashmi Chugh, Lakshmi P. Kunju, Moshe Talpaz, Anne F. Schott, Arul M. Chinnaiyan - Nature Genetics 2013 被引用: 1,158

  5. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    著者: Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Siu‐Fun Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian - New England Journal of Medicine 2013 被引用: 1,124

  6. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    著者: Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F. Apperley, H. Jean Khoury, Moshe Talpaz, Daniel J. DeAngelo, Elisabetta Abruzzese, Delphine Réa, Michele Baccarani, Martin C. Müller, Carlo Gambacorti‐Passerini, Stephanie Lustgarten, Victor M. Rivera, Frank G. Haluska, François Guilhot, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Hagop M. Kantarjian - Blood 2018 被引用: 583

  7. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

    著者: Brian Druker, Moshe Talpaz, Debra Resta, Bin Peng, Elisabeth Buchdunger, J. Ford, Nicholas Lydon, Hagop M. Kantarjian, Renaud Capdeville, Sayuri Ohno-Jones, Charles L. Sawyers - New England Journal of Medicine 2001 被引用: 5,241

  8. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

    著者: Jörge E. Cortes, Jane F. Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Arthur, Lori J. Maness, Moshe Talpaz, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger - Blood 2021 被引用: 193

  9. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis

    著者: John Mascarenhas, Ronald Hoffman, Moshe Talpaz, Aaron T. Gerds, Brady L. Stein, Vikas Gupta, Anita Szőke, Mark W. Drummond, Alexander Pristupa, Tanya Granston, Robert Daly, Suliman Al‐Fayoumi, Jennifer Callahan, Jack W. Singer, Jason Gotlib, Catriona Jamieson, Claire Harrison, Ruben A. Mesa, Srđan Verstovšek - JAMA Oncology 2018 被引用: 380

  10. Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo

    著者: Dmitry Borkin, Shihan He, Hongzhi Miao, Katarzyna Kempińska, Jonathan Pollock, Jennifer Chase, Trupta Purohit, Bhavna Malik, Ting C. Zhao, Jingya Wang, Bo Wen, Hongliang Zong, Morgan Jones, Gwenn Danet-Desnoyers, Mónica L. Guzmán, Moshe Talpaz, Dale L. Bixby, Duxin Sun, Jay L. Hess, Andrew G. Muntean, Ivan Maillard, Tomasz Cierpicki, Jolanta Grembecka - Cancer Cell 2015 被引用: 402

  11. Identification of Targetable FGFR Gene Fusions in Diverse Cancers

    著者: Yi-Mi Wu, Fengyun Su, Shanker Kalyana‐Sundaram, Nickolay A. Khazanov, Bushra Ateeq, Xuhong Cao, Robert J. Lonigro, Pankaj Vats, Rui Wang, Su‐Fang Lin, Ann‐Joy Cheng, Lakshmi P. Kunju, Javed Siddiqui, Scott A. Tomlins, Peter Wyngaard, Seth Sadis, Sameek Roychowdhury, Maha Hussain, Felix Y. Feng, Mark M. Zalupski, Moshe Talpaz, Kenneth J. Pienta, Daniel R. Rhodes, Dan R. Robinson, Arul M. Chinnaiyan - Cancer Discovery 2013 被引用: 738

  12. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

    著者: for the COMFORT-I investigators, Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark M. Jones, Deanna Kornacki, Kang Sun, Hagop M. Kantarjian - Journal of Hematology & Oncology 2017 被引用: 427

  13. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

    著者: Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Ramón V. Tiu, Pierre Zachée, Éric Jourdan, Elliott F. Winton, Richard T. Silver, Harry C. Schouten, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Joanne Lager, Zhenming Shun, Ruben A. Mesa - The Lancet Haematology 2017 被引用: 330

  14. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

    著者: Moshe Talpaz, Jean‐Jacques Kiladjian - Leukemia 2020 被引用: 184

  15. Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

    著者: Vaibhav Kapuria, Luke F. Peterson, Dexing Fang, William G. Bornmann, Moshe Talpaz, Nicholas J. Donato - Cancer Research 2010 被引用: 395

  16. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

    著者: John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Mariëlle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Srđan Verstovšek, Natalia Curto‐García, Claire Harrison, Vikas Gupta - Journal of Clinical Oncology 2023 被引用: 85

  17. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    著者: Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jörge E. Cortes, Susan O’Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers - New England Journal of Medicine 2006 被引用: 1,772

  18. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

    著者: Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Ruben A. Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark Heaney, Casey L. O’Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann - Blood Advances 2020 被引用: 123

  19. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

    著者: Neil P. Shah, Ravi Bhatia, Jessica K. Altman, Maria L. Amaya, Kebede H. Begna, Ellin Berman, Onyee Chan, Joan Clements, Robert H. Collins, Peter Curtin, Daniel J. DeAngelo, Michael W. Drazer, Lori J. Maness, Leland Metheny, Sanjay Mohan, Joseph O. Moore, Vivian G. Oehler, Keith W. Pratz, Iskra Pusic, Michal G. Rose, William Shomali, B. Douglas Smith, Michael Styler, Moshe Talpaz, Tiffany Tanaka, Srinivas K. Tantravahi, James E. Thompson, Steven Tsai, Jennifer E. Vaughn, Jeanna Welborn, David T. Yang, Hema Sundar, Kristina M. Gregory - Journal of the National Comprehensive Cancer Network 2024 被引用: 118

  20. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

    著者: Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian, Debra Resta, Sofia Fernandes Reese, J. Ford, Renaud Capdeville, Moshe Talpaz - New England Journal of Medicine 2001 被引用: 2,723

  21. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

    著者: Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula Bockenstedt, Erica Campagnaro, Sumana Devata, Scott D. Gitlin, Mark Kaminski, Alice Cusick, Tycel Phillips, Suman L. Sood, Moshe Talpaz, Albert Quiery, Philip S. Boonstra, Ryan A. Wilcox - The Lancet Haematology 2019 被引用: 259

  22. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

    著者: Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, Delphine Réa, Jörge E. Cortes, Andreas Hochhaus, Koji Sasaki, Massimo Breccia, Moshe Talpaz, Oliver G. Ottmann, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Michael C. Heinrich, Valle Gómez-Garcı́a de Soria, Philipp le Coutre, François‐Xavier Mahon, Jeroen J. W. M. Janssen, Michael W. Deininger, Naranie Shanmuganathan, Mark B. Geyer, Silvia Cacciatore, Fotis Polydoros, Nithya Agrawal, Matthias Hoch, Fabian Lang - Leukemia 2023 被引用: 47

  23. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    著者: Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, Dale L. Bixby, Michael J. Mauro, Ian W. Flinn, Thomas O’Hare, Simin Hu, Narayana I. Narasimhan, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Brian Druker, Michael W. Deininger, Moshe Talpaz - New England Journal of Medicine 2012 被引用: 770

  24. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

    著者: Jeffrey H. Lipton, Charles Chuah, Agnès Guerci‐Bresler, Gianantonio Rosti, David Simpson, Sarit Assouline, Gabriel Étienne, Franck E. Nicolini, Philipp le Coutre, Richard E Clark, Leif Stenke, David Andorsky, Vivian G. Oehler, Stephanie Lustgarten, Victor M. Rivera, Timothy Piers Clackson, Frank G. Haluska, Michele Baccarani, Jörge E. Cortes, François Guilhot, Andreas Hochhaus, Timothy P. Hughes, Hagop M. Kantarjian, Neil P. Shah, Moshe Talpaz, Michael Deininger - The Lancet Oncology 2016 被引用: 259